Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 237

1.

Prolyl isomerase Pin1 negatively regulates the stability of SUV39H1 to promote tumorigenesis in breast cancer.

Khanal P, Kim G, Lim SC, Yun HJ, Lee KY, Choi HK, Choi HS.

FASEB J. 2013 Nov;27(11):4606-18. doi: 10.1096/fj.13-236851. Epub 2013 Aug 9.

2.

COT phosphorylates prolyl-isomerase Pin1 to promote tumorigenesis in breast cancer.

Kim G, Khanal P, Kim JY, Yun HJ, Lim SC, Shim JH, Choi HS.

Mol Carcinog. 2015 Jun;54(6):440-8. doi: 10.1002/mc.22112. Epub 2013 Nov 22.

PMID:
24265246
3.

Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability.

Lam PB, Burga LN, Wu BP, Hofstatter EW, Lu KP, Wulf GM.

Mol Cancer. 2008 Dec 15;7:91. doi: 10.1186/1476-4598-7-91.

4.

Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells.

Khanal P, Yun HJ, Lim SC, Ahn SG, Yoon HE, Kang KW, Hong R, Choi HS.

Oncogene. 2012 Aug 23;31(34):3845-56. doi: 10.1038/onc.2011.548. Epub 2011 Dec 12.

PMID:
22158035
5.

Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase.

Min SH, Lau AW, Lee TH, Inuzuka H, Wei S, Huang P, Shaik S, Lee DY, Finn G, Balastik M, Chen CH, Luo M, Tron AE, Decaprio JA, Zhou XZ, Wei W, Lu KP.

Mol Cell. 2012 Jun 29;46(6):771-83. doi: 10.1016/j.molcel.2012.04.012. Epub 2012 May 17.

6.

Cancer-associated upregulation of histone H3 lysine 9 trimethylation promotes cell motility in vitro and drives tumor formation in vivo.

Yokoyama Y, Hieda M, Nishioka Y, Matsumoto A, Higashi S, Kimura H, Yamamoto H, Mori M, Matsuura S, Matsuura N.

Cancer Sci. 2013 Jul;104(7):889-95. doi: 10.1111/cas.12166. Epub 2013 May 15.

7.

Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma.

Chiba T, Saito T, Yuki K, Zen Y, Koide S, Kanogawa N, Motoyama T, Ogasawara S, Suzuki E, Ooka Y, Tawada A, Otsuka M, Miyazaki M, Iwama A, Yokosuka O.

Int J Cancer. 2015 Jan 15;136(2):289-98. doi: 10.1002/ijc.28985. Epub 2014 May 30.

8.

Prolyl isomerase Pin1 downregulates tumor suppressor RUNX3 in breast cancer.

Nicole Tsang YH, Wu XW, Lim JS, Wee Ong C, Salto-Tellez M, Ito K, Ito Y, Chen LF.

Oncogene. 2013 Mar 21;32(12):1488-96. doi: 10.1038/onc.2012.178. Epub 2012 May 14.

9.

Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation.

Liao Y, Wei Y, Zhou X, Yang JY, Dai C, Chen YJ, Agarwal NK, Sarbassov D, Shi D, Yu D, Hung MC.

Oncogene. 2009 Jul 2;28(26):2436-45. doi: 10.1038/onc.2009.98. Epub 2009 May 18.

10.

The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production.

Pastorino L, Sun A, Lu PJ, Zhou XZ, Balastik M, Finn G, Wulf G, Lim J, Li SH, Li X, Xia W, Nicholson LK, Lu KP.

Nature. 2006 Mar 23;440(7083):528-34. Erratum in: Nature. 2007 Mar 15;446(7133):342.

PMID:
16554819
11.

Death-associated protein kinase 1 phosphorylates Pin1 and inhibits its prolyl isomerase activity and cellular function.

Lee TH, Chen CH, Suizu F, Huang P, Schiene-Fischer C, Daum S, Zhang YJ, Goate A, Chen RH, Zhou XZ, Lu KP.

Mol Cell. 2011 Apr 22;42(2):147-59. doi: 10.1016/j.molcel.2011.03.005. Epub 2011 Apr 14.

12.

Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer.

Wei S, Kozono S, Kats L, Nechama M, Li W, Guarnerio J, Luo M, You MH, Yao Y, Kondo A, Hu H, Bozkurt G, Moerke NJ, Cao S, Reschke M, Chen CH, Rego EM, Lo-Coco F, Cantley LC, Lee TH, Wu H, Zhang Y, Pandolfi PP, Zhou XZ, Lu KP.

Nat Med. 2015 May;21(5):457-66. doi: 10.1038/nm.3839. Epub 2015 Apr 13.

13.

The prolyl isomerase pin1 regulates mRNA levels of genes with short half-lives by targeting specific RNA binding proteins.

Krishnan N, Titus MA, Thapar R.

PLoS One. 2014 Jan 9;9(1):e85427. doi: 10.1371/journal.pone.0085427. eCollection 2014.

14.

The role of Pin1 in the development and treatment of cancer.

Min SH, Zhou XZ, Lu KP.

Arch Pharm Res. 2016 Dec;39(12):1609-1620. doi: 10.1007/s12272-016-0821-x. Epub 2016 Aug 29. Review.

PMID:
27572155
15.

A critical step for JNK activation: isomerization by the prolyl isomerase Pin1.

Park JE, Lee JA, Park SG, Lee DH, Kim SJ, Kim HJ, Uchida C, Uchida T, Park BC, Cho S.

Cell Death Differ. 2012 Jan;19(1):153-61. doi: 10.1038/cdd.2011.82. Epub 2011 Jun 10.

16.

The prolyl isomerase Pin1 enhances HER-2 expression and cellular transformation via its interaction with mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1.

Khanal P, Namgoong GM, Kang BS, Woo ER, Choi HS.

Mol Cancer Ther. 2010 Mar;9(3):606-16. doi: 10.1158/1535-7163.MCT-09-0560. Epub 2010 Feb 23.

17.
18.

[Pin1: a multi-talented peptidyl prolyl cis-trans isomerase and a promising therapeutic target for human cancers].

Marsolier J, Weitzman JB.

Med Sci (Paris). 2014 Aug-Sep;30(8-9):772-8. doi: 10.1051/medsci/20143008015. Epub 2014 Sep 1. Review. French.

19.

Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem-like cell traits in breast cancer.

Luo ML, Gong C, Chen CH, Lee DY, Hu H, Huang P, Yao Y, Guo W, Reinhardt F, Wulf G, Lieberman J, Zhou XZ, Song E, Lu KP.

Cancer Res. 2014 Jul 1;74(13):3603-16. doi: 10.1158/0008-5472.CAN-13-2785. Epub 2014 May 1.

20.

Supplemental Content

Support Center